Climb Bio, Inc. (CLYM) vs Zevra Therapeutics, Inc. (ZVRA)
- Climb Bio, Inc. CLYM 9.82 −9.99%
- Zevra Therapeutics, Inc. ZVRA 9.95 −3.12%
Climb Bio, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. Climb Bio, Inc. and Zevra Therapeutics, Inc. are of similar size ($626.6M and $609.9M). Climb Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 10.5×. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs 0.00%) and the higher return on invested capital (0.00% vs −71.7%). Across the 12 metrics below, Zevra Therapeutics, Inc. leads on 10 and Climb Bio, Inc. on 2.
Valuation
Profitability
| Metric | CLYM | ZVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 95.46% | 65.16% |
| Operating margin | 0.00% | 60.54% | 0.00% |
| Net margin | 0.00% | 42.25% | 0.00% |
| Free cash flow margin | 0.00% | 24.30% | 0.00% |
| Return on equity | (27.10%) | 34.33% | (56.36%) |
| Return on assets | (26.27%) | 20.57% | (48.04%) |
| Return on invested capital | (71.73%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack